Enoxaparin Sodium

Please Wait

Applying Filters...

FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

Data Compilation
#PharmaFlow

Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

Stock Recap
#PipelineProspector

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

34 API Suppliers, 14 USDMF, 3 CEP/COS, 5 KDMF, 8 NDC API, 19 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

42 Drugs in Development

42 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

471 FDF Dossiers, 69 FDA Orange Book, 228 Europe, 44 Canada, 40 Australia, 18 South Africa, 72 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - 100MG/ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 120MG/0.8ML (150MG/ML), INJECTABLE;SUBCUTANEOUS - 150MG/ML (150MG/ML), INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 300MG/3ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 30MG/0.3ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 40MG/0.4ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 60MG/0.6ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 80MG/0.8ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 1 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

2 Topical, 1 Parenteral, 1 Solubilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 35 News #PharmaBuzz

GLOBAL SALES INFORMATION

16 US Medicaid Prescriptions, 34 Regulatory FDF Prices, 11 Annual Reports

MARKET PLACE

41 APIs, 69 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 Health Canada Patents

4 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 4 Others

$ Xls

Filters

INJECTABLE;SUBCUTANEOUS - 100MG/ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 120MG/0.8ML (150MG/ML)

INJECTABLE;SUBCUTANEOUS - 150MG/ML (150MG/ML)

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 300MG/3ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 30MG/0.3ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 40MG/0.4ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 60MG/0.6ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 80MG/0.8ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

X

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.